Prosight Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Prosight Management’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-176,900	Closed	-$4.86M	–	41
2024 Q4	$4.86M	Buy	+176,900	New	+$4.93M	1.34%	22
2024 Q1	–	Sell	-120,000	Closed	-$4.88M	–	46
2023 Q4	$4.88M	Buy	+120,000	New	+$4.42M	1.96%	15
2023 Q2	–	Sell	-40,000	Closed	-$1.55M	–	41
2023 Q1	$1.55M	Hold	40,000	–	–	0.73%	30
2022 Q4	$1.78M	Buy	+40,000	New	+$1.68M	0.97%	26
2022 Q2	–	Sell	-195,000	Closed	-$12.1M	–	29
2022 Q1	$12.1M	Sell	195,000 -5,300	-3%	-$324K	7.81%	4
2021 Q4	$11M	Buy	200,300 +100,300	+100%	+$5.23M	6.61%	4
2021 Q3	$5.26M	Buy	+100,000	New	+$5.94M	2.89%	12

Other funds holding LKFT

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

DCM

DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Prosight Management's LKFT Position: Q2 2026 in Review

Prosight Management increased its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 32% in Q2 2026, buying an estimated $14M and bringing the position to 2,043,344 shares worth $61.3M. The position accounts for 10.56% of the portfolio, ranked #1.

Prosight Management first reported a position in LKFT in Q4 2018 and has held it in 23 quarters since. 76 funds tracked by Wall St. Rank hold LKFT as of Q2 2026.

Prosight Management held 2,043,344 shares of Lakefront Biotherapeutics American Depositary Shares worth $61.3M as of Q2 2026.
Prosight Management bought 493,344 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2026, an estimated $14M.
Lakefront Biotherapeutics American Depositary Shares made up 10.56% of Prosight Management's portfolio in Q2 2026, its #1 holding.
Prosight Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2018 and has held it in 23 quarters since.
76 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2026.

Based on Prosight Management's 13F filing for Q2 2026, filed 14 Aug 2026.